These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 37633929)
41. Mass spectrometry-based proteomics: a useful tool for biomarker discovery? Gramolini AO; Peterman SM; Kislinger T Clin Pharmacol Ther; 2008 May; 83(5):758-60. PubMed ID: 18388886 [TBL] [Abstract][Full Text] [Related]
42. The evolving role of mass spectrometry in cancer biomarker discovery. Wang P; Whiteaker JR; Paulovich AG Cancer Biol Ther; 2009 Jun; 8(12):1083-94. PubMed ID: 19502776 [TBL] [Abstract][Full Text] [Related]
43. Sample Treatment for Tissue Proteomics in Cancer, Toxicology, and Forensics. Cole LM; Clench MR; Francese S Adv Exp Med Biol; 2019; 1073():77-123. PubMed ID: 31236840 [TBL] [Abstract][Full Text] [Related]
44. Proteomics: the next revolution in laboratory medicine? Plebani M Clin Chim Acta; 2005 Jul; 357(2):113-22. PubMed ID: 15941565 [TBL] [Abstract][Full Text] [Related]
46. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Stepczynska A; Schanstra JP; Mischak H Bioanalysis; 2016; 8(5):439-55. PubMed ID: 26891752 [TBL] [Abstract][Full Text] [Related]
47. Application of machine learning to proteomics data: classification and biomarker identification in postgenomics biology. Swan AL; Mobasheri A; Allaway D; Liddell S; Bacardit J OMICS; 2013 Dec; 17(12):595-610. PubMed ID: 24116388 [TBL] [Abstract][Full Text] [Related]
48. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Robinson RA; Amin B; Guest PC Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223 [TBL] [Abstract][Full Text] [Related]
49. The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development. Mikami T; Aoki M; Kimura T Curr Mol Pharmacol; 2012 Jun; 5(2):301-16. PubMed ID: 22122469 [TBL] [Abstract][Full Text] [Related]
50. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. de Wit M; Fijneman RJ; Verheul HM; Meijer GA; Jimenez CR Clin Biochem; 2013 Apr; 46(6):466-79. PubMed ID: 23159294 [TBL] [Abstract][Full Text] [Related]
54. Perspectives for imaging mass spectrometry in the proteomics landscape. MacAleese L; Stauber J; Heeren RM Proteomics; 2009 Feb; 9(4):819-34. PubMed ID: 19212956 [TBL] [Abstract][Full Text] [Related]
55. A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. Vidova V; Spacil Z Anal Chim Acta; 2017 Apr; 964():7-23. PubMed ID: 28351641 [TBL] [Abstract][Full Text] [Related]
56. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Kim KH; Kim JY; Yoo JS Expert Rev Proteomics; 2019 Jul; 16(7):553-568. PubMed ID: 31145639 [No Abstract] [Full Text] [Related]
58. Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics. Timms JF; Hale OJ; Cramer R Expert Rev Proteomics; 2016 Jun; 13(6):593-607. PubMed ID: 27109265 [TBL] [Abstract][Full Text] [Related]
59. Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders. Venugopal A; Chaerkady R; Pandey A Ann Indian Acad Neurol; 2009 Jan; 12(1):3-11. PubMed ID: 20151002 [TBL] [Abstract][Full Text] [Related]
60. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. Whiteaker JR; Zhang H; Zhao L; Wang P; Kelly-Spratt KS; Ivey RG; Piening BD; Feng LC; Kasarda E; Gurley KE; Eng JK; Chodosh LA; Kemp CJ; McIntosh MW; Paulovich AG J Proteome Res; 2007 Oct; 6(10):3962-75. PubMed ID: 17711321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]